JP2004534788A5 - - Google Patents

Download PDF

Info

Publication number
JP2004534788A5
JP2004534788A5 JP2003502981A JP2003502981A JP2004534788A5 JP 2004534788 A5 JP2004534788 A5 JP 2004534788A5 JP 2003502981 A JP2003502981 A JP 2003502981A JP 2003502981 A JP2003502981 A JP 2003502981A JP 2004534788 A5 JP2004534788 A5 JP 2004534788A5
Authority
JP
Japan
Prior art keywords
combination
optionally substituted
macrocyclic lactone
receptor
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003502981A
Other languages
English (en)
Japanese (ja)
Other versions
JP4476623B2 (ja
JP2004534788A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/006278 external-priority patent/WO2002100148A2/en
Publication of JP2004534788A publication Critical patent/JP2004534788A/ja
Publication of JP2004534788A5 publication Critical patent/JP2004534788A5/ja
Application granted granted Critical
Publication of JP4476623B2 publication Critical patent/JP4476623B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003502981A 2001-06-08 2002-06-07 インスリン産生細胞移植片拒絶の処置または予防 Expired - Fee Related JP4476623B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29706901P 2001-06-08 2001-06-08
PCT/EP2002/006278 WO2002100148A2 (en) 2001-06-08 2002-06-07 Treatment or prophylaxis of insulin-producing cell graft rejection

Publications (3)

Publication Number Publication Date
JP2004534788A JP2004534788A (ja) 2004-11-18
JP2004534788A5 true JP2004534788A5 (enExample) 2005-12-22
JP4476623B2 JP4476623B2 (ja) 2010-06-09

Family

ID=23144725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003502981A Expired - Fee Related JP4476623B2 (ja) 2001-06-08 2002-06-07 インスリン産生細胞移植片拒絶の処置または予防

Country Status (18)

Country Link
US (5) US20030003099A1 (enExample)
EP (1) EP1429845B1 (enExample)
JP (1) JP4476623B2 (enExample)
CN (1) CN1524002A (enExample)
AT (1) ATE424893T1 (enExample)
AU (1) AU2002320828B2 (enExample)
BR (1) BR0209319A (enExample)
CA (1) CA2445605A1 (enExample)
DE (1) DE60231522D1 (enExample)
ES (1) ES2322442T3 (enExample)
IL (1) IL158384A0 (enExample)
NO (1) NO20035434D0 (enExample)
NZ (1) NZ529044A (enExample)
PL (1) PL364359A1 (enExample)
PT (1) PT1429845E (enExample)
RU (1) RU2003136730A (enExample)
WO (1) WO2002100148A2 (enExample)
ZA (1) ZA200307893B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4318921B2 (ja) * 2001-02-22 2009-08-26 ノバルティス アクチエンゲゼルシャフト 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用
EP2338511A3 (en) * 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
CN101905023B (zh) * 2004-07-16 2012-07-11 杏林制药株式会社 有效的医药使用方法及与副作用发生的防御相关的方法
EP2384749A1 (en) * 2004-11-29 2011-11-09 Novartis AG Dosage regimen of an S1P receptor agonist
AU2006212866A1 (en) * 2005-02-08 2006-08-17 Novartis Ag Antilymphocyte antibody induction by combination of an S1P receptor agonist/modulator and of immunosuppressive drugs
WO2006124375A2 (en) * 2005-05-11 2006-11-23 Loma Linda University Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders
US20090191218A1 (en) 2005-05-11 2009-07-30 Fengchun Li DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
RU2433117C2 (ru) 2005-12-15 2011-11-10 Мицубиси Танабе Фарма Корпорейшн Аминное соединение и его применение в медицинских целях
BRPI0708424A2 (pt) * 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
WO2008039980A2 (en) * 2006-09-28 2008-04-03 Loma Linda University Apoptotic cell-mediated transfection of mammalian cells with interfering rna
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
AU2009223148B2 (en) * 2008-03-12 2013-03-14 Loma Linda University DNA vaccines and methods for the prevention of transplantation rejection
CA2716448A1 (en) 2008-03-17 2009-09-24 Patrick Brossard Dosing regimen for a selective s1p1 receptor agonist
JP2012508215A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
CN104788325A (zh) * 2008-11-11 2015-07-22 诺华股份有限公司 芬戈莫德的结晶形式
CA2766944C (en) * 2009-06-30 2019-10-29 Lifescan, Inc. Analyte testing methods and device for calculating basal insulin therapy
CA2766870A1 (en) * 2009-06-30 2011-01-06 Lifescan Scotland Limited Systems for diabetes management and methods
CN103976741B (zh) * 2009-09-29 2017-02-22 生命扫描苏格兰有限公司 用于糖尿病管理的被分析物测试方法和装置
CN102770868B (zh) * 2010-02-25 2017-02-22 生命扫描苏格兰有限公司 具有高低血糖趋势通知的分析物测试方法和系统
WO2013044177A2 (en) 2011-09-23 2013-03-28 Loma Linda University Bacterial strains expressing methylase genes and uses thereof
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
CN114306643A (zh) * 2021-11-30 2022-04-12 中国科学院昆明动物研究所 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155015B1 (ko) * 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
CA2184356A1 (en) * 1994-03-03 1995-09-08 Russell P. Rother Terminal complement inhibitor fusion genes and proteins
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP4318921B2 (ja) * 2001-02-22 2009-08-26 ノバルティス アクチエンゲゼルシャフト 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用

Similar Documents

Publication Publication Date Title
RU2009143333A (ru) Производные аминодигидротиазина, замещенные циклической группой
JP2004516314A5 (enExample)
JP2005506352A5 (enExample)
JP2008514732A5 (enExample)
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
RU2013107007A (ru) Бифункциональные соединения, являющиеся ингибиторами rho-киназы, композиция и применение
JP2006501181A5 (enExample)
JP2009532453A5 (enExample)
KR20180132939A (ko) 암 치료를 위한 조합 요법
JP2008510691A5 (enExample)
JP2013532652A5 (enExample)
JP2005533775A5 (enExample)
JP2004531544A5 (enExample)
JP2008535902A5 (enExample)
RU2003136730A (ru) Лечение или профилактика отторжения инсулин-продуцирующего клеточного трансплантата
RU2006137794A (ru) Химические составы, композиции и способы их использования
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
CN1277553A (zh) 血管生成促进剂和血管生成增效剂
JP2009511508A5 (enExample)
JP2012519691A5 (enExample)
RU99112577A (ru) Новое применение 1,3-пропандиольных производных
EP2077846A4 (en) BENZOXAZEPINE COMPOUNDS, PREPARATION THEREOF AND USE THEREOF
RU2012110380A (ru) Новое производное 5-фторурацила
RU2012109554A (ru) Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией
JP2022505268A5 (enExample)